RedHill Biopharma Ltd.(RDHL)Earnings, Financials & Key Ratios
RDHL•NASDAQ
$1.01
$5M mkt cap·Price updated May 7, 2026
AboutRedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.Show more
- Revenue$8M+23.2%
- EBITDA-$14M-195.7%
- Net Income-$8M-134.6%
- EPS (Diluted)-7.00-115.2%
- Gross Margin60.31%+28.2%
- EBITDA Margin-173.99%-177.7%
- Operating Margin-181.69%-193.9%
- Net Margin-102.8%-128.1%
- Interest Coverage-265.69-871.9%
RDHL Key Insights
RedHill Biopharma Ltd. (RDHL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 1155.9%
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
RDHL Price & Volume
RedHill Biopharma Ltd. (RDHL) stock price & volume — 10-year historical chart
Loading chart...
RDHL Growth Metrics
RedHill Biopharma Ltd. (RDHL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years1.38%
5 Years5.04%
3 Years-54.57%
TTM157.62%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM69.14%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM90.7%
Return on Capital
10 Years-33.82%
5 Years9.65%
3 Years95.91%
Last Year-
RDHL Peer Comparison
RedHill Biopharma Ltd. (RDHL) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CMPX | 250.3M | 1.81 | -4.31 | -100% | -39.75% | 0.05 | ||
 PRAX | 9.63B | 333.28 | -24.72 | -100% | -43.02% | 0.00 | ||
 IRWD | 679.95M | 4.17 | 27.80 | -15.72% | 41.76% | |||
 SUPN | 3.01B | 52.28 | -76.88 | 8.63% | -3.74% | -2.73% | 0.04 | |
 PTGX | 6.36B | 98.85 | -48.22 | -89.41% | -6.48% | -17.76% | 0.02 | |
 ARWR | 10.92B | 77.95 | -6389.34 | 232.58% | -48.38% | -55.47% | 0.73 | |
 PAHC | 1.75B | 43.16 | 36.27 | 27.37% | 6.29% | 30.81% | 2.67 | |
 MNKD | 1.1B | 3.55 | 177.50 | 22.23% | -6.63% |
Compare RDHL vs Peers
RedHill Biopharma Ltd. (RDHL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RDHL Income Statement
RedHill Biopharma Ltd. (RDHL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 101K | 4.01M | 8.36M | 6.29M | 64.36M | 85.76M | 61.8M | 6.53M | 8.04M | 9.55M |
| Revenue Growth % | 3266.67% | 3867.33% | 108.63% | -24.75% | 923.03% | 33.25% | -27.94% | -89.43% | 23.17% | 157.62% |
| Cost of Goods Sold | 30.54M | 2.13M | 2.84M | 2.26M | 36.89M | 49.41M | 33.34M | 3.46M | 3.19M | 3.4M |
| COGS % of Revenue | 30240.59% | 53.06% | 33.94% | 35.91% | 57.32% | 57.61% | 53.94% | 52.97% | 39.69% | - |
| Gross Profit | -30.44M▲ 0% | 1.88M▲ 106.2% | 5.52M▲ 193.6% | 4.03M▼ 27.0% | 27.47M▲ 581.2% | 36.35M▲ 32.3% | 28.46M▼ 21.7% | 3.07M▼ 89.2% | 4.85M▲ 58.0% | 6.16M▲ 0% |
| Gross Margin % | -30140.59% | 46.94% | 66.06% | 64.09% | 42.68% | 42.39% | 46.06% | 47.03% | 60.31% | 64.45% |
| Gross Profit Growth % | -38.38% | 106.18% | 193.62% | -27% | 581.23% | 32.34% | -21.7% | -89.21% | 57.96% | - |
| Operating Expenses | 30.64M | 53.85M | 44.85M | 47.23M | 91.15M | 117.49M | 71.31M | -9.56M | 19.46M | 16.7M |
| OpEx % of Revenue | 30340.59% | 1343.97% | 536.53% | 750.8% | 141.63% | 137% | 115.38% | -146.42% | 242% | - |
| Selling, General & Admin | 5.4M | 20.04M | 19.99M | 29.81M | 74.66M | 87.99M | 64.03M | 30.98M | 15.52M | 12.45M |
| SG&A % of Revenue | 5349.51% | 500.1% | 239.14% | 473.92% | 116.01% | 102.6% | 103.61% | 474.35% | 192.93% | - |
| Research & Development | 25.24M | 32.97M | 24.86M | 17.42M | 16.49M | 29.5M | 7.28M | 3.53M | 1.59M | 1.89M |
| R&D % of Revenue | 24991.09% | 822.79% | 297.39% | 276.89% | 25.62% | 34.4% | 11.78% | 54.03% | 19.74% | - |
| Other Operating Expenses | 0 | 845K | 0 | 0 | 0 | 0 | 0 | -44.06M | 2.36M | 2M |
| Operating Income | -30.54M▲ 0% | -51.97M▼ 70.2% | -39.33M▲ 24.3% | -43.2M▼ 9.8% | -63.68M▼ 47.4% | -81.14M▼ 27.4% | -42.84M▲ 47.2% | 12.63M▲ 129.5% | -14.61M▼ 215.7% | -10.54M▲ 0% |
| Operating Margin % | -30240.59% | -1297.03% | -470.47% | -686.71% | -98.95% | -94.61% | -69.33% | 193.45% | -181.69% | -110.4% |
| Operating Income Growth % | -38.82% | -70.16% | 24.32% | -9.84% | -47.41% | -27.4% | 47.19% | 129.48% | -215.68% | - |
| EBITDA | -30.5M | -51.89M | -39.24M | -41.99M | -54.94M | -62.99M | -34.69M | 14.62M | -13.99M | -10.26M |
| EBITDA Margin % | -30197.03% | -1295.01% | -469.39% | -667.43% | -85.36% | -73.45% | -56.13% | 223.92% | -173.99% | -107.48% |
| EBITDA Growth % | -38.85% | -70.14% | 24.38% | -7% | -30.84% | -14.65% | 44.92% | 142.15% | -195.71% | 47.38% |
| D&A (Non-Cash Add-back) | 44K | 81K | 90K | 1.21M | 8.74M | 18.15M | 8.15M | 1.99M | 619K | 278.5K |
| EBIT | -30.54M | -45.54M | -38.82M | -41.91M | -63.72M | -81.18M | -30.34M | 24.28M | -8.21M | -8.18M |
| Net Interest Income | 275K | 220K | 237K | 5.02K | -12.27M | -16.58M | -41.19M | -273K | 78K | 802K |
| Interest Income | 282K | 6.5M | 678K | 444.43K | 176K | 51K | 140K | 94K | 133K | 1.83M |
| Interest Expense | 7K | 77K | 167K | 439.42K | 12.45M | 16.57M | 41.33M | 367K | 55K | 1.02M |
| Other Income/Expense | 1.17M | 6.43M | 511K | 897K | -12.49M | -16.61M | -28.82M | 11.28M | 6.34M | 1.23M |
| Pretax Income | -29.37M▲ 0% | -45.54M▼ 55.1% | -38.82M▲ 14.8% | -42.3M▼ 9.0% | -76.17M▼ 80.1% | -97.74M▼ 28.3% | -71.67M▲ 26.7% | 23.92M▲ 133.4% | -8.27M▼ 134.6% | -9.31M▲ 0% |
| Pretax Margin % | -29079.21% | -1136.61% | -464.35% | -672.45% | -118.36% | -113.98% | -115.97% | 366.25% | -102.8% | -97.52% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -29.37M▲ 0% | -45.54M▼ 55.1% | -38.82M▲ 14.8% | -42.3M▼ 9.0% | -76.17M▼ 80.1% | -97.74M▼ 28.3% | -71.67M▲ 26.7% | 23.92M▲ 133.4% | -8.27M▼ 134.6% | -9.31M▲ 0% |
| Net Margin % | -29079.21% | -1136.61% | -464.35% | -672.45% | -118.36% | -113.98% | -115.97% | 366.25% | -102.8% | -97.52% |
| Net Income Growth % | -39.26% | -55.07% | 14.76% | -8.97% | -80.06% | -28.32% | 26.68% | 133.37% | -134.57% | 69.14% |
| Net Income (Continuing) | -29.37M | -45.54M | -38.82M | -42.3M | -76.17M | -97.74M | -71.67M | 23.92M | -8.27M | -9.31M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1100.00▲ 0% | -1300.00▼ 18.2% | -850.00▲ 34.6% | -700.00▲ 17.6% | -1000.00▼ 42.9% | -1000.00▲ 0.0% | -600.00▲ 40.0% | 46.00▲ 107.7% | -7.00▼ 115.2% | -5.17▲ 0% |
| EPS Growth % | -15.79% | -18.18% | 34.62% | 17.65% | -42.86% | 0% | 40% | 107.67% | -115.22% | 90.7% |
| EPS (Basic) | -1100.00 | -1300.00 | -850.00 | -700.00 | -1000.00 | -1000.00 | -600.00 | 46.00 | -7.00 | - |
| Diluted Shares Outstanding | 25.76K | 35.31K | 46.24K | 59.38K | 72.85K | 93.05K | 123.86K | 518.24K | 2.46M | 1.8M |
| Basic Shares Outstanding | 25.7K | 35.31K | 46.24K | 59.38K | 72.85K | 93.05K | 123.86K | 518.24K | 2.46M | 1.8M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
RDHL Balance Sheet
RedHill Biopharma Ltd. (RDHL) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 67.81M | 51.68M | 56.79M | 53.21M | 70.5M | 89.15M | 85.9M | 16.14M | 11.91M | 12.55M |
| Cash & Short-Term Investments | 66.15M | 46.2M | 53.19M | 47.87M | 29.79M | 38M | 19.98M | 6.36M | 4.62M | 2.87M |
| Cash Only | 53.79M | 16.45M | 29M | 29.02M | 29.3M | 29.47M | 19.97M | 5.57M | 4.62M | 2.87M |
| Short-Term Investments | 12.37M | 29.75M | 24.18M | 18.85M | 498K | 8.53M | 15K | 790.04K | 0 | 0 |
| Accounts Receivable | 492K | 2.26M | 1.4M | 1.64M | 29.29M | 32.52M | 37.88M | 3.29M | 3.57M | 6.36M |
| Days Sales Outstanding | 1.78K | 206.05 | 60.91 | 94.86 | 166.11 | 138.43 | 223.7 | 183.62 | 161.83 | 170.22 |
| Inventory | 1.11M | 653K | 769K | 1.88M | 6.53M | 14.81M | 11.01M | 4.39M | 3.65M | 3.17M |
| Days Inventory Outstanding | 13.31 | 112.11 | 98.94 | 304.09 | 64.57 | 109.41 | 120.54 | 463.14 | 417.49 | 366.61 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 16M | 797.04K | 0 | 160K |
| Total Non-Current Assets | 6.4M | 5.67M | 5.62M | 20.89M | 109.75M | 92.04M | 72.97M | 6.91M | 6.13M | 5.82M |
| Property, Plant & Equipment | 165K | 230K | 163K | 3.81M | 5.7M | 4.22M | 7.19M | 1.18M | 437K | 289K |
| Fixed Asset Turnover | 0.61x | 17.42x | 51.29x | 1.65x | 11.29x | 20.31x | 8.59x | 5.52x | 18.41x | 26.31x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 6.09M | 5.29M | 5.32M | 16.93M | 87.88M | 71.64M | 65.63M | 5.58M | 5.55M | 5.53M |
| Long-Term Investments | 137K | 152K | 140K | 152K | 0 | 16.17M | 150K | 147K | 148K | 0 |
| Other Non-Current Assets | 137K | 152K | -5.62M | -20.73M | 32.33M | 16.17M | 150K | 41 | 0 | 296K |
| Total Assets | 74.21M▲ 0% | 57.34M▼ 22.7% | 62.41M▲ 8.8% | 74.1M▲ 18.7% | 180.24M▲ 143.2% | 181.19M▲ 0.5% | 158.87M▼ 12.3% | 23.05M▼ 85.5% | 18.04M▼ 21.7% | 18.38M▲ 0% |
| Asset Turnover | 0.00x | 0.07x | 0.13x | 0.08x | 0.36x | 0.47x | 0.39x | 0.28x | 0.45x | 0.52x |
| Asset Growth % | 11.05% | -22.73% | 8.84% | 18.73% | 143.24% | 0.53% | -12.32% | -85.49% | -21.71% | -76.56% |
| Total Current Liabilities | 5.36M | 11.83M | 10.38M | 10.62M | 73.23M | 81.47M | 197.45M | 19.24M | 22.22M | 22.29M |
| Accounts Payable | 60K | 4.8M | 3.32M | 4.18M | 11.55M | 11.66M | 4.23M | 3.28M | 7.86M | 835K |
| Days Payables Outstanding | 0.72 | 824.94 | 427.66 | 676.03 | 114.3 | 86.17 | 46.31 | 345.9 | 898.89 | 287.57 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 1.71M | 1.62M | 115.22M | 718K | 353K | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 5.49M | 19.51M | 37.31M | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 393K | 1.06M | 1.46M | -2.89M | -1.71M | 12.03M | 49.65M | 10.76M | 10.96M | 10.55M |
| Current Ratio | 12.66x | 4.37x | 5.47x | 5.01x | 0.96x | 1.09x | 0.44x | 0.84x | 0.54x | 0.54x |
| Quick Ratio | 12.45x | 4.31x | 5.40x | 4.84x | 0.87x | 0.91x | 0.38x | 0.61x | 0.37x | 0.37x |
| Cash Conversion Cycle | 1.79K | -506.78 | -267.81 | -277.09 | 116.37 | 161.67 | 297.92 | 300.85 | -319.58 | 249.27 |
| Total Non-Current Liabilities | 6.16M | 448K | 844K | 3.48M | 93.14M | 90.84M | 9.82M | 1.74M | 503K | 500K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 81.39M | 83.62M | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 2.98M | 3.81M | 2.57M | 6.44M | 455K | 3K | 6K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 6.16M | 448K | 844K | 500K | 7.95M | 4.65M | 3.37M | 540K | 500K | 2M |
| Total Liabilities | 11.51M | 12.28M | 11.22M | 14.1M | 166.38M | 172.31M | 207.27M | 20.98M | 22.73M | 22.79M |
| Total Debt | 0 | 0 | 0 | 3.81M | 86.9M | 87.81M | 122.69M | 1.17M | 356K | 214K |
| Net Debt | -53.79M | -16.45M | -29M | -25.21M | 57.61M | 58.34M | 102.72M | -4.4M | -4.26M | -2.65M |
| Debt / Equity | - | - | - | 0.06x | 6.27x | 9.89x | - | 0.57x | - | -0.05x |
| Debt / EBITDA | - | - | - | - | - | - | - | 0.08x | - | -0.02x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | -0.30x | - | 0.26x |
| Interest Coverage | -4363.29x | -674.96x | -235.51x | -98.31x | -5.12x | -4.90x | -1.04x | 34.42x | -265.69x | -7.99x |
| Total Equity | 62.7M▲ 0% | 45.06M▼ 28.1% | 51.19M▲ 13.6% | 60M▲ 17.2% | 13.86M▼ 76.9% | 8.88M▼ 36.0% | -48.4M▼ 645.4% | 2.07M▲ 104.3% | -4.68M▼ 326.3% | -4.41M▲ 0% |
| Equity Growth % | 4.37% | -28.13% | 13.58% | 17.22% | -76.89% | -35.99% | -645.35% | 104.27% | -326.34% | -15318.26% |
| Book Value per Share | 2434.05 | 1276.12 | 1106.96 | 1010.41 | 190.30 | 95.37 | -390.77 | 3.99 | -1.90 | -2.45 |
| Total Shareholders' Equity | 62.7M | 45.06M | 51.19M | 60M | 13.86M | 8.88M | -48.4M | 2.07M | -4.68M | -4.41M |
| Common Stock | 441K | 575K | 767K | 962K | 1.05M | 1.5M | 2.83M | 21.44M | 35.04M | 63.4M |
| Retained Earnings | -89.64M | -132.94M | -169.09M | -208.36M | -280.33M | -367.87M | -433.86M | -407.74M | -414.8M | -418.12M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -170K | -251K | -341K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RDHL Cash Flow Statement
RedHill Biopharma Ltd. (RDHL) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -28.26M | -44.77M | -34.46M | -40.75M | -48.58M | -65.05M | -29.18M | -35.82M | -9.37M | -9.37M |
| Operating CF Margin % | -27978.22% | -1117.27% | -412.22% | -647.73% | -75.48% | -75.85% | -47.22% | -548.55% | -116.49% | - |
| Operating CF Growth % | -58.52% | -58.43% | 23.02% | -18.24% | -19.22% | -33.9% | 55.13% | -22.73% | 73.84% | 202.54% |
| Net Income | -29.37M | -45.54M | -38.82M | -42.3M | -76.17M | -97.74M | -71.67M | 23.92M | -8.27M | -9.31M |
| Depreciation & Amortization | 44K | 81K | 90K | 1.21M | 8.74M | 18.15M | 8.15M | 1.99M | 619K | 369K |
| Stock-Based Compensation | 1.68M | 2.23M | 2.68M | 3.03M | 4.2M | 10.21M | 5.67M | 1.65M | 665K | 733K |
| Deferred Taxes | -1.26M | -5.08M | 136K | 0 | 195K | 123K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 94K | -123K | 35K | -347K | 6.03M | 5.37M | 20.65M | -47.79M | -4.44M | -602K |
| Working Capital Changes | 553K | 3.66M | 1.42M | -2.34M | 8.42M | -1.15M | 8.01M | -15.58M | 2.05M | 614K |
| Change in Receivables | 713.24K | -1.43M | 570K | -258K | -27.44M | -3.02M | -2.85M | 33.43M | 52K | -4.38M |
| Change in Inventory | 0 | -653K | -116K | -1.11M | -4.64M | -8.29M | 3.8M | 2.38M | 738K | 635K |
| Change in Payables | -158K | 4.75M | -1.48M | 860K | 7.37M | 111K | -7.43M | -949.55K | -2.11M | 0 |
| Cash from Investing | 24.47M | -18.58M | 5.35M | 5.16M | -35.65M | -8.14M | 8.3M | 3.99K | -9K | -12K |
| Capital Expenditures | -120K | -1.18M | -58K | -203K | -53.77M | -115K | -198K | -10.97K | -9K | -12K |
| CapEx % of Revenue | 118.81% | 29.47% | 0.69% | 3.23% | 83.55% | 0.13% | 0.32% | 0.17% | 0.11% | - |
| Acquisitions | -36.87M | 11.96M | 35K | 35K | 0 | 8.03M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 36.87M | -11.96M | -35K | -35K | 0 | -8.03M | 0 | 0 | 0 | 0 |
| Cash from Financing | 36.02M | 25.65M | 41.76M | 35.51M | 84.37M | 73.46M | 11.45M | 21.38M | 8.42M | 3.78M |
| Debt Issued (Net) | 0 | 0 | 0 | -796K | 76.45M | -1.68M | -1.48M | -1.18M | -636K | 0 |
| Equity Issued (Net) | 35.75M | 22.22M | 41.9M | 36.3M | 23.87M | 78.54M | 23.81M | 13.92M | 8.26M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 263K | 3.44M | -139K | 5K | -15.95M | -3.39M | -10.88M | 8.64M | 790K | 3.78M |
| Net Change in Cash | 32.27M▲ 0% | -37.33M▼ 215.7% | 12.55M▲ 133.6% | 18K▼ 99.9% | 272K▲ 1411.1% | 179K▼ 34.2% | -9.51M▼ 5410.6% | -14.4M▼ 51.5% | -952K▲ 93.4% | -7.28M▲ 0% |
| Free Cash Flow | -28.38M▲ 0% | -45.95M▼ 61.9% | -34.52M▲ 24.9% | -40.95M▼ 18.6% | -102.35M▼ 149.9% | -65.16M▲ 36.3% | -29.38M▲ 54.9% | -35.83M▼ 21.9% | -9.38M▲ 73.8% | -8.21M▲ 0% |
| FCF Margin % | -28097.03% | -1146.74% | -412.92% | -650.96% | -159.03% | -75.98% | -47.55% | -548.71% | -116.6% | -85.98% |
| FCF Growth % | -45.83% | -61.92% | 24.87% | -18.63% | -149.93% | 36.34% | 54.91% | -21.94% | 73.83% | 66.12% |
| FCF per Share | -1101.63 | -1301.18 | -746.54 | -689.61 | -1404.91 | -700.26 | -237.23 | -69.14 | -3.81 | -3.81 |
| FCF Conversion (FCF/Net Income) | 0.96x | 0.98x | 0.89x | 0.96x | 0.64x | 0.67x | 0.41x | -1.50x | 1.13x | 0.88x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 55K | 37K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RDHL Key Ratios
RedHill Biopharma Ltd. (RDHL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -47.84% | -84.52% | -80.66% | -76.09% | -206.25% | -859.7% | - | 1155.91% | - | 204.79% |
| Return on Invested Capital (ROIC) | -96.5% | -207.75% | -116.16% | -113.74% | -89.89% | -87.75% | -52.88% | 36.44% | - | 108.02% |
| Gross Margin | -30140.59% | 46.94% | 66.06% | 64.09% | 42.68% | 42.39% | 46.06% | 47.03% | 60.31% | 64.45% |
| Net Margin | -29079.21% | -1136.61% | -464.35% | -672.45% | -118.36% | -113.98% | -115.97% | 366.25% | -102.8% | -97.52% |
| Debt / Equity | - | - | - | 0.06x | 6.27x | 9.89x | - | 0.57x | - | -0.05x |
| Interest Coverage | -4363.29x | -674.96x | -235.51x | -98.31x | -5.12x | -4.90x | -1.04x | 34.42x | -265.69x | -7.99x |
| FCF Conversion | 0.96x | 0.98x | 0.89x | 0.96x | 0.64x | 0.67x | 0.41x | -1.50x | 1.13x | 0.88x |
| Revenue Growth | 3266.67% | 3867.33% | 108.63% | -24.75% | 923.03% | 33.25% | -27.94% | -89.43% | 23.17% | 157.62% |
RDHL Frequently Asked Questions
RedHill Biopharma Ltd. (RDHL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
RedHill Biopharma Ltd. (RDHL) reported $9.5M in revenue for fiscal year 2024. This represents a 41422% increase from $0.0M in 2011.
RedHill Biopharma Ltd. (RDHL) grew revenue by 23.2% over the past year. This is strong growth.
RedHill Biopharma Ltd. (RDHL) reported a net loss of $9.3M for fiscal year 2024.
Dividend & Returns
RedHill Biopharma Ltd. (RDHL) had negative free cash flow of $8.2M in fiscal year 2024, likely due to heavy capital investments.
Explore More RDHL
RedHill Biopharma Ltd. (RDHL) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates